Phase 1 study of M2698, a p70S6K/AKT dual inhibitor, in patients with advanced cancer

Overview of attention for article published in Journal of Hematology & Oncology, August 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#26 of 1,293)
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

So far, Altmetric has seen 12 news stories from 11 outlets.

DIACC3010, formerly M2698, is a Phase II-ready dual PAM inhibitor with rare brain-penetration properties Merck KGaA, Darmstadt…

DIACC3010, formerly M2698,, is a Phase II-ready dual PAM inhibitor with rare brain-penetration properties Merck KGaA, Darmstadt…

PARIS, FRANCE / ACCESSWIRE / September 8, 2021 / Diaccurate, a French biotech company that develops sole-in-class drug…

zielgerichtete Krebstherapie im Stadium der klinischen Entwicklung Für den Inhalt..."> DGAP-News: DIACCURATE SAS / Schlagwort(e)…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity, including 8 additional news stories.